HomeNewsDusa

Dusa

Jump to

Sun Pharma rises 4% ahead of Q2 nos, Taro's earnings strong

Taro's sales grew 28 percent year-on-year. Its operating profits grew faster at 46 percent led by 740 basis points margin expansion. Religare has hiked its target price to Rs 725.
What to expect from Sun Pharma in Q4

Sun Pharmaceutical Indusries' fourth quarter revenues may rise by 26 percent year-on-year to Rs 2,946 crore during the March quarter.
Sun Pharma: Can the stock climb higher than all-time high?

Sun Pharma was at lifetime high yesterday at Rs 854. It has received final approval for Novartis's Reclast/Aclasta, which is used in the treatment of osteoporosis.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Dusa

Sun Pharma rises 4% ahead of Q2 nos, Taro's earnings strong

What to expect from Sun Pharma in Q4

Sun Pharma: Can the stock climb higher than all-time high?